Q: Please provide some information if you can on this non-Canada Company ENDO. I bought a thousand shares last fall real cheap, sold half in December to lock in a nice profit. Rebought the half shares. It has gone up nicely again. Does it have the legs to go to $10? Thank you Gord

Q: I owned Paladin and was very happy with the sale to ENDP, but I, regrettably, held my shares of ENDO until I lost most if not all of my Paladin windfall. You endorsed ENDO and saw future growth there. Now that TSGI has been sold, I am wondering what to do. I realize there is some deal risk and regulatory risk, and I am not fond of the inconvenience of the London Exchange. I am thinking I might sell my TSGI shares and put the proceeds split into LSPD and/or SHOP. I know you see growth in all three, but you have perhaps been endorsing LSPD and SHOP for longer, now. And you took TSGI out of the portfolio (before the sale, I realize). To focus my question, let me ask: How do the two Canadian stocks compare to TSGI in terms of risks/rewards going forward. The 2 for 1 would at least add a bit of diversification.

Q: A guest on Market Call commented on Endo as a possible generic drug winner, albeit somewhat speculative as other small caps in this category. I would appreciate your assessment on this stock. Thank you!